Beigene

This study is testing a new drug called BGB-11417 for people with certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The goal is to find the safest dose and see if the drug works on its own or when combined with another cancer medic…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.

This study tests the drug zanubrutinib in 18 Chinese adults with Waldenström macroglobulinemia who have not yet received treatment. The goal is to see how well the drug controls the cancer and to check for side effects. Participants take the drug by mouth, and the study will meas…

This study tests an experimental drug called tislelizumab in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The drug works by helping the immune system attack cancer cells. About 200 participants who have already tried other treatments will …

This study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…

This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This early-stage study tests a new drug called BG-T187, which is designed to attach to two cancer-related targets (EGFR and MET) to attack tumor cells. About 87 adults with advanced solid tumors that have not responded to prior treatments will receive the drug alone or with other…

This study tests a new drug called BGB-45035 for the first time in humans. It will check safety and how the body processes the drug in healthy volunteers, then test it in people with autoimmune skin diseases like eczema and prurigo nodularis. The goal is to see if the drug is saf…

This study is looking at how well the drug zanubrutinib works and how safe it is for people with Waldenström macroglobulinemia, a rare type of blood cancer. Researchers will track 111 participants from different racial and ethnic backgrounds, including those with specific genetic…